कंपनी का अवलोकन
Evolus, Inc. operates as a performance beauty company dedicated to delivering aesthetic products within the cash-pay market across the United States, Canada, Europe, and Australia. The firm specializes in manufacturing and selling medical-grade injectables, most notably Jeuveau, which utilizes a proprietary 900 kilodalton purified botulinum toxin type A formulation to temporarily improve the appearance of moderate facial lines. This entity functions within the broader Healthcare sector, specifically under the industry classification of Drug Manufacturers - Specialty & Generic, indicating its focus on niche pharmaceutical solutions rather than mass-market commodities. The company maintains a substantial operational footprint with 334 employees supporting its global distribution network. Its current market capitalization stands at $275.85M, while annual revenue (TTM) is recorded at $297.18M, reflecting a mid-cap enterprise that has achieved significant market penetration in the aesthetic medicine space. These valuation and revenue figures suggest that the company has established a robust revenue base sufficient to fund R&D and marketing efforts, positioning it as a significant player in the specialized drug manufacturing landscape despite its relatively smaller scale compared to major pharmaceutical giants.
वित्तीय स्वास्थ्य
The company reported total revenue of $297.18M for the trailing twelve months, yet it recorded a net income of -$51.64M and an EBITDA of -$30.09M, highlighting a substantial divergence between top-line growth and bottom-line profitability. This significant gap between revenue and net income reveals a heavy cost structure, likely driven by high research and development expenditures, manufacturing costs associated with proprietary formulations, or substantial marketing outlays required to capture market share in the competitive aesthetic sector. Furthermore, the company generated a free cash flow of -$26.69M, indicating that current cash generation is insufficient to cover operational cash burn without external financing or asset liquidation. Regarding margins, the gross margin stands at 66.3%, which is healthy for a specialty drug manufacturer and suggests efficient production and supply chain management relative to sales prices. However, the operating margin is -0.3% and the profit margin is -17.4%, indicating that operating expenses are consuming nearly the entire gross profit, preventing the realization of net earnings. On the balance sheet, the company holds $53.83M in cash against $155.00M in debt, creating a net debt position, while the debt-to-equity ratio is listed as N/A due to the lack of shareholder equity. The current ratio is 1.90, which signifies a strong short-term liquidity position where current assets are nearly double the current liabilities, providing a comfortable buffer for meeting immediate obligations. Return on Equity is N/A as there is no positive equity base, and Return on Assets is -10.3%, demonstrating that the company's asset base is currently generating negative returns on an accounting basis.
मूल्यांकन आकलन
The valuation metrics present a complex picture, with a forward P/E ratio of 17.67 while the trailing P/E ratio is N/A due to the absence of net income. The existence of a forward P/E implies that the market prices in expected future earnings recovery, whereas the lack of a trailing P/E confirms that the company has not yet generated positive earnings over the last twelve months. The price-to-book ratio is -11.94, a negative figure that indicates the market capitalizes the company at a value significantly below its book value, often seen in growth-stage biotech or specialty drug firms where current earnings are negative. Additionally, the price-to-sales ratio is 0.93 and the EV/EBITDA is -12.53, suggesting that investors are valuing the firm primarily on revenue multiples rather than earnings power or cash flow generation. The stock's 52-week high is $12.28 and the 52-week low is $3.86, providing a clear trading range that illustrates the volatility and sentiment shifts experienced by the security over the past year. The beta value is 1.00, which indicates that the stock's price volatility moves in tandem with the broader market, lacking the defensive characteristics of utilities or the high-beta aggression of small-cap tech stocks.
Growth & Income
Revenue growth year-over-year is 14.4%, demonstrating a healthy expansion in the top line driven by market demand for aesthetic treatments. Earnings growth is N/A because the company is currently unprofitable, meaning that revenue expansion has not yet translated into earnings growth, a typical characteristic of companies investing heavily in future growth potential. The company does not pay a dividend, as the dividend yield is N/A and the payout ratio is 0.0%, which confirms that all available resources are being retained within the business to fund operations, R&D, and debt reduction rather than being distributed to shareholders. This reinvestment strategy is consistent with the company's lifecycle stage, where capital allocation focuses on scaling the business and establishing market dominance rather than providing immediate income to investors. Consequently, the overall growth and income profile is defined by top-line expansion without current earnings power or dividend yield, relying on future profitability to drive stock appreciation.